GlaxoSmithKline has resolved a class action lawsuit over its “Big Bad Cough” advertising campaign for the BOOSTRIX vaccine, paying $50 per eligible claimant to settle claims that the marketing misrepresented the pharmaceutical company’s pertussis vaccine. The case, DeCostanzo v. GlaxoSmithKline plc et al., centers on the multimedia campaign featuring anthropomorphic wolves that ran between 2015 and 2020, which plaintiffs alleged made misleading or unsupported claims about the vaccine’s effectiveness.
While GSK disputes the allegations and did not admit liability as part of the settlement agreement, the company agreed to resolve the dispute through the Angeion Group, a professional settlement administrator that has begun notifying eligible class members about their right to claim compensation. The settlement applies to consumers who received the BOOSTRIX vaccine between May 20, 2016 and May 20, 2020 specifically to protect someone else from whooping cough, though the broader implications extend to how pharmaceutical companies market vaccines and the standards courts use to evaluate vaccine advertising claims. The claim filing deadline is June 8, 2026, meaning eligible individuals have a limited window to submit documentation proving their eligibility for the $50 payment.
Table of Contents
- What Made the “Big Bad Cough” Campaign Controversial?
- Understanding the Class and Eligibility Requirements
- How Settlement Administration Works and Timeline Matters
- What the Settlement Does and Doesn’t Include
- The Distinction Between No Liability Admission and Settlement Value
- BOOSTRIX and the Pertussis Protection Question
- Claim Filing Procedures and Documentation Requirements
What Made the “Big Bad Cough” Campaign Controversial?
The “Big Bad Cough” marketing campaign became the focal point of this litigation because of how it depicted whooping cough and the vaccine’s protective qualities. Rather than using conventional pharmaceutical advertising with doctors and clinical data, GSK deployed animated wolves as the central metaphor for the “big bad” pertussis infection, creating memorable television and digital advertisements intended to drive vaccine adoption.
This creative approach was part of a broader strategy to make vaccine advertising more engaging and less clinical, but it also exposed GSK to claims that the campaign oversimplified the vaccine’s effects or made assertions not fully supported by clinical evidence. Marketing-driven pharmaceutical litigation has become increasingly common in recent years, with courts examining whether advertisements comply with FDA regulations and whether claims made to consumers go beyond what clinical studies actually demonstrate. The “Big Bad Cough” campaign represents a middle ground between direct-to-consumer vaccine advertising and healthcare provider materials, making it a particularly vulnerable target for legal scrutiny since it had to satisfy both entertainment standards and medical accuracy standards simultaneously.
Understanding the Class and Eligibility Requirements
The legal definition of the class in this settlement is narrow and specific: only individuals who received the BOOSTRIX vaccine between May 20, 2016 and May 20, 2020 to protect someone else from whooping cough qualify for compensation. This means someone who received the vaccine to protect their own health from pertussis would not be part of the eligible class, even if they were exposed to the same advertising. This distinction matters because the plaintiffs’ argument centered on whether consumers were misled about the vaccine’s protective benefit specifically in the context of protecting others—a narrower claim than arguing the vaccine was ineffective generally.
Eligible class members must provide documentation to the Angeion Group proving they received the vaccine during the specified period and that the vaccination was administered for the purpose of protecting someone else. This requirement means individuals need medical records, vaccination cards, or provider statements showing the date and reason for vaccination. Without proper documentation, claims will be denied, so individuals who received BOOSTRIX during this window should locate their medical records before the June 8, 2026 deadline passes.
How Settlement Administration Works and Timeline Matters
The Angeion Group’s role as settlement administrator involves receiving claim forms, verifying eligibility, and distributing the $50 payments to approved claimants. Settlement administrators operate independently from both the defendant company and the law firms involved in the case, serving as neutral third parties that ensure the settlement is executed fairly and according to court approval. Angeion Group has announced the proposed settlement and begun the notification process, meaning class members should be receiving or have already received notices about their eligibility and the deadline.
Claim filing deadlines in class action settlements are strictly enforced, and June 8, 2026 represents a hard cutoff after which the Angeion Group will no longer accept new claims, even if documentation arrives days later. Unlike some settlements that allow late filings for good cause, pharmaceutical settlement deadlines are typically absolute. Individuals who believe they qualify should prioritize gathering documentation and submitting claims well before the deadline to avoid missing out on the $50 payment.
What the Settlement Does and Doesn’t Include
The $50 per-claimant payment represents the full recovery available through this settlement, with no additional compensation for individual claims even if someone believes they suffered greater harm from relying on the advertising. Class action settlements almost always cap recovery at a uniform amount per claimant rather than allowing individual damage awards, which is a significant limitation for anyone who incurred substantial medical expenses or other costs they believe resulted from the misleading advertising. The tradeoff is that uniform payments allow settlements to resolve large groups of claims quickly without requiring individual trials or case-by-case proof of damages.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Importantly, the settlement does not include an admission of liability from GlaxoSmithKline, meaning the company has not conceded that the “Big Bad Cough” campaign was actually misleading or that the vaccine’s claims were false. Instead, GSK paid the settlement amount to resolve the dispute without confirming the plaintiffs’ allegations. This is a common structure in pharmaceutical settlements but represents a limitation for class members who sought vindication of their claims—the settlement provides compensation but not necessarily confirmation that the advertising was wrongful.
The Distinction Between No Liability Admission and Settlement Value
The fact that GSK disputes the allegations and did not admit liability might seem contradictory to paying $50 per claimant, but this structure is standard in pharmaceutical litigation and reflects how companies evaluate settlement costs versus litigation risk. GSK weighed the expense of continued litigation, discovery costs, potential jury verdict, and reputational impact against the total settlement payout, and determined that settlement made financial and strategic sense despite maintaining that the advertising was appropriate. This does not mean the advertising was accurate or that consumers were not misled—it means only that GSK chose to settle rather than litigate the question further.
Consumers who received the vaccine and see the settlement notice might reasonably ask whether they were actually misled if the company does not admit wrongdoing. The answer is that settlements are business decisions, not verdicts. A no-liability-admission settlement can be rational for a company even if the underlying claims have merit, particularly in cases involving vaccine advertising where continued litigation attracts regulatory scrutiny and negative media coverage that extends far beyond the courtroom.
BOOSTRIX and the Pertussis Protection Question
BOOSTRIX is a combination vaccine protecting against pertussis, tetanus, and diphtheria (Tdap), with particular emphasis in the marketing around whooping cough prevention. Pertussis is a serious respiratory infection that can be life-threatening in infants and young children, which is why vaccinating adults and adolescents to protect vulnerable individuals has become standard medical practice. The vaccine provides protection to the vaccinated person but is also part of a broader public health strategy called “cocooning,” where caregivers and close contacts receive vaccination to prevent spreading pertussis to babies too young for their own vaccination series.
The “Big Bad Cough” campaign leveraged this public health angle in its advertising, specifically encouraging people to get vaccinated to protect others. This made the campaign especially targeted toward parents, grandparents, and healthcare workers who interacted with infants. If the campaign overstated how well the vaccine protected others from infection, or if it misrepresented the duration of protection, the claims would resonate with people who made vaccination decisions based specifically on protecting vulnerable family members.
Claim Filing Procedures and Documentation Requirements
Individuals who believe they are part of this settlement class should visit the official settlement website at bigbadcoughsettlement.com to obtain detailed instructions on filing claims and the specific documentation required by the Angeion Group. Most pharmaceutical settlement claims require either an original vaccination record, a statement from the healthcare provider who administered the vaccine, or insurance records showing the vaccination date and the reason it was administered.
Pharmacy records or state immunization registries may also provide acceptable documentation if original records are unavailable. The settlement administrator will review all submitted claims and issue determinations on eligibility within a specified timeframe after the June 8, 2026 deadline passes. Claimants who are denied can typically request reconsideration or an appeal, but these processes are also subject to deadlines, making it critical to file initially within the claim period rather than attempting to appeal after missing the primary deadline entirely.
- —
You Might Also Like
- Capital Health Data Breach Settlement Resolves Claims Over Hospital Cyberattack
- NextEra Nuclear Plant Wage Class Action Settlement Resolves Claims Worker Pay Was Suppressed
- Equity Residential Rent Antitrust Settlement Resolves Claims Apartment Prices Were Inflated